Comparative Pharmacology
Head-to-head clinical analysis: LOW OGESTREL 28 versus NORTREL 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOW OGESTREL 28 versus NORTREL 7 7 7.
LOW-OGESTREL-28 vs NORTREL 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol and norgestrel inhibit ovulation via suppression of gonadotropins (LH, FSH); increase viscosity of cervical mucus, impairing sperm penetration; alter endometrial structure, reducing implantation likelihood.
Combination estrogen-progestin oral contraceptive. Suppresses gonadotropin release, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 28 days, with 21 active tablets followed by 7 inactive tablets.
One tablet orally once daily, taken at the same time each day. Each tablet contains norethindrone 0.5 mg/ethinyl estradiol 35 mcg for days 1-7, norethindrone 0.75 mg/ethinyl estradiol 35 mcg for days 8-14, and norethindrone 1 mg/ethinyl estradiol 35 mcg for days 15-21, followed by 7 placebo tablets.
None Documented
None Documented
Norgestrel: ~45 hours (terminal). Ethinyl estradiol: ~13 hours (terminal). Steady-state achieved within 5-7 days.
Norelgestromin terminal half-life is approximately 28 hours; ethinyl estradiol terminal half-life is approximately 17 hours. The extended half-life supports once-weekly dosing.
Renal 50-60% as metabolites, fecal 40-50% via biliary elimination. Ethinyl estradiol undergoes enterohepatic recirculation.
Renal excretion of metabolites (primarily ethinyl estradiol and norelgestromin conjugates) accounts for approximately 50% of elimination; fecal/biliary excretion accounts for the remainder (about 35-40% fecal, 10-15% biliary).
Category C
Category C
Oral Contraceptive
Oral Contraceptive